Herbal Dispatch Reports Q4 2025 Gross Sales of $6.2 Million, Achieves Positive Adjusted EBITDA, and Reports Full Year Gross Sales of $16.5 Million

Herbal Dispatch shows real sales growth, but profitability and transparency remain unresolved risks.

What the company is saying

Herbal Dispatch Inc. wants investors to see a company in the midst of a strong turnaround, emphasizing rapid revenue growth and improving profitability. The core narrative is that Herbal Dispatch is a 'leading operator' in Canadian cannabis e-commerce, delivering quality products at competitive prices and now expanding internationally. Management highlights a 115% year-over-year jump in Q4 gross sales, improved gross margins, and a move toward positive adjusted EBITDA as proof of operational momentum. The announcement repeatedly frames these improvements as evidence of a scalable, profitable business model, with language like 'well-positioned to create long-term value for shareholders' and 'path to sustained profitability.' The company also spotlights its oversubscribed $2.1 million private placement and new OTCQB listing as validation of investor interest and market credibility. However, the release buries or omits key details: there is no breakdown of export sales, no segment or customer data, and no explicit discussion of regulatory or competitive risks. The tone is upbeat and confident, with management—specifically Philip Campbell, President & CEO—projecting control and optimism but offering little in the way of caution or downside scenarios. Campbell's dual role as CEO and Director signals continuity but does not introduce outside institutional validation. This narrative fits a classic growth-company IR strategy: focus on headline growth, downplay losses, and defer tough questions about cash flow or market share. Compared to prior communications (where available), the messaging here is consistent with a company trying to shift investor focus from past losses to recent operational improvements, but without providing the granular evidence that would fully substantiate its leadership claims.

What the data suggests

The disclosed numbers show Herbal Dispatch is growing quickly but remains unprofitable. Q4 2025 gross sales hit $6.2 million, up 115% from $2.9 million in Q4 2024, and net revenue rose to $4.1 million from $2.3 million. For the full year, gross sales increased 37% to $16.5 million, and net revenue reached $12.1 million, up from $9.9 million. Adjusted EBITDA improved from $(1.0) million in FY 2024 to $(0.7) million in FY 2025, with Q4 2025 showing a small positive of $0.1 million. Gross margin expanded from 20.1% to 22.7%, and gross profit grew to $2.75 million from $2.0 million. Net loss narrowed from $(2,773,049) in FY 2024 to $(1,841,467) in FY 2025, but the company is still losing money. The gap between narrative and numbers is most obvious in the lack of detail: there is no segment breakdown, no cash flow statement, and no export sales data to support claims of international expansion. Prior targets or guidance are not referenced, so it's unclear if management is meeting its own benchmarks. The financial disclosures are adequate for headline metrics but lack the granularity needed for a full operational assessment. An independent analyst would conclude that while the growth is real and losses are shrinking, Herbal Dispatch is not yet sustainably profitable, and the absence of detailed disclosures limits confidence in the company's long-term claims.

Analysis

The announcement presents a positive tone, highlighting strong year-over-year growth in gross sales, net revenue, and improved adjusted EBITDA. Most key claims are realised and supported by disclosed numerical data, such as the 115% increase in Q4 gross sales and improved gross margin. However, some language inflates the company's position, such as describing itself as a 'leading operator' and referencing 'active expansion through exports' without providing supporting data or specifics. The forward-looking statements are present but limited in number and scope, mainly focusing on continued improvement and international expansion. There is no evidence of a large capital outlay with only long-dated returns; the $2.1 million private placement is disclosed as completed and not tied to speculative future benefits. The gap between narrative and evidence is moderate, with most hype stemming from qualitative positioning rather than unsupported financial projections.

Risk flags

• ●Operational risk remains high: While sales are growing, Herbal Dispatch is still unprofitable on a net basis, with a FY 2025 net loss of $(1,841,467). This means the company must continue to execute flawlessly just to reach break-even, and any operational misstep could quickly erode recent gains.
• ●Disclosure risk is material: The announcement omits key financial details such as cash flow, segment performance, and specific export sales figures. This lack of transparency makes it difficult for investors to assess the sustainability of growth or the true drivers of margin improvement.
• ●Forward-looking risk is significant: A substantial portion of the company's narrative is based on future international expansion and long-term value creation, but there is no evidence or timeline provided for these claims. Investors are being asked to trust in management's ability to deliver on unproven initiatives.
• ●Capital intensity and dilution risk: The company completed a $2.1 million private placement in October 2025, which was oversubscribed. While this signals investor interest, it also suggests ongoing capital needs and the potential for future dilution if profitability is not achieved soon.
• ●Execution risk in new markets: The company claims to be expanding exports to international markets, but provides no data on which markets, regulatory hurdles, or competitive landscape. International cannabis expansion is notoriously complex and failure to execute could result in sunk costs with little return.
• ●Pattern risk from selective disclosure: The announcement highlights positive metrics but omits any discussion of regulatory, competitive, or operational challenges. This pattern of selective disclosure can be a red flag, as it may indicate management is downplaying material risks.
• ●Timeline risk for value realization: The most bullish claims—such as sustained profitability and international growth—are not expected to materialize in the near term. Investors face the risk of capital being tied up for years before any payoff, with no guarantee of success.
• ●Leadership concentration risk: Philip Campbell serves as both President & CEO and Director, which centralizes decision-making. While this can provide continuity, it also means there is less independent oversight, increasing the risk of unchecked strategic errors.

Bottom line

For investors, this announcement confirms that Herbal Dispatch is growing quickly and narrowing its losses, but it is not yet a profitable or fully transparent business. The headline numbers—115% Q4 sales growth, improved gross margin, and a smaller net loss—are real and supported by the disclosed data. However, the company continues to lose money, and the absence of cash flow, segment, and export sales details makes it hard to judge whether this growth is sustainable or simply the result of aggressive spending. There are no notable institutional investors or outside validation in this announcement; the $2.1 million private placement was oversubscribed, but the participants are not named, and this does not guarantee future institutional support. To change this assessment, Herbal Dispatch would need to provide detailed segment and export sales data, cash flow statements, and clear evidence of profitability or market leadership. In the next reporting period, investors should watch for sustained positive adjusted EBITDA, narrowing net losses, and concrete evidence of international sales. This announcement is a weak positive signal—worth monitoring, but not strong enough to justify new investment without further evidence. The single most important takeaway is that while Herbal Dispatch is moving in the right direction, the company is not yet out of the woods, and investors should demand more transparency and proof of sustainable profitability before committing capital.

Announcement summary

Herbal Dispatch Inc. (CSE: HERB, OTCQB: LUFFF) announced its financial results for the fourth quarter and year ended December 31, 2025. The company reported Q4 2025 gross sales of $6.2 million, a 115% increase from $2.9 million in Q4 2024, and net revenue of $4.1 million, up from $2.3 million. Adjusted EBITDA for Q4 2025 was $0.1 million, compared to $(0.6) million in Q4 2024, and for the full year 2025, adjusted EBITDA improved to $(0.7) million from $(1.0) million in 2024. The company completed an oversubscribed non-brokered private placement raising $2.1 million in October 2025 and commenced trading on the OTCQB Venture Market under the ticker LUFFF. Gross margin improved to approximately 22.7% in 2025, compared to 20.1% in 2024.

Disagree with this article?